Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hackett, G.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Schedule 11 — impact on treating erectile dysfunction

Geoff Hackett

Department of Urology, Good Hope Hospital, Rectory Road, Sutton Coldfield, West Midlands, B75 7RR, UK, ghac876762{at}aol.com

Since 1998, NHS therapy for erectile dysfunction (ED) has only been available under schedule 11 regulations. This involves restriction to certain medical conditions and restrictions of the quantity of medications. A new category was introduced, namely a patient confirmed by a consultant as suffering from `severe distress'. Recent evidence suggests that ED is closely related to many important men's health issues and that restricting access to therapy in this way is both wasteful of resources and leading to missed healthcare opportunities. In the light of recent evidence, certain aspects of schedule 11 need to be reviewed.

Key Words: schedule 11 • erectile dysfunction.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 4, 315-318 (2002)
DOI: 10.1177/14746514020020041701
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
K. J Snow
Erectile dysfunction in patients with diabetes mellitus -- advances in treatment with phosphodiesterase type 5 inhibitors
The British Journal of Diabetes & Vascular Disease, July 1, 2002; 2(4): 282 - 287.
[Abstract] [PDF]